FDA's 2026 Vape Enforcement Shift: What Changed

In May 2026, the FDA issued new enforcement guidance that, for the first time, explicitly separated "technically unauthorized" from "worth prioritizing for enforcement." Our earlier coverage described the visible result of this shift (large numbers of disposables still circulating on the market) — this piece fills in the full logic behind it, plus the data that's come in since.

A three-tier enforcement priority framework

The guidance draws three clear enforcement priority tiers:

1. Authorized products — lowest risk, with only about 39-45 products (the exact count creeps up slowly over time) actually holding a Marketing Granted Order
2. Products with a PMTA on file, under review — lower enforcement priority; as long as a genuine application is moving through the review pipeline, it isn't a near-term enforcement target even without a decision yet
3. Products that never filed, or were denied — the highest enforcement priority, and where the 2026 border seizure budget is concentrated

This three-tier framework explains something that used to be confusing: why so many "technically unauthorized" disposables remain available through US retail channels — they likely sit in tier two, already filed and waiting through what remains an extremely slow review process. (We break down exactly why that process is so slow, and how expensive, in our PMTA economics piece — worth reading alongside this one.)

Where the $200 million border budget actually goes

The FY2026 federal appropriation requires the FDA/CBP to spend no less than $200 million combating illegal vapes, with funding directed at:

• Expanding dedicated vape inspection capacity at ports of entry
• The September 2025 joint FDA/CBP operation in Chicago, which set the record for the largest single seizure to date — operations like this are expected to become more frequent
• Tracing warehousing and distribution for tier-three (never-filed or denied) products specifically

State-level rules layer on top — don't overlook them

Beyond the federal PMTA framework, individual states are running their own product registries — some states require a vape product to appear on a state-authorized product list before it can be sold at retail there. This registry doesn't automatically track federal PMTA status, which can create a gap: a product sitting in the lower-priority federal tier might still be non-compliant at the state level simply because it's missing from that state's list. Evaluating market access for a specific state can't stop at the federal enforcement-tier question alone.

Practical guidance for sourcing and channel planning

• Prioritize confirming a supplier's PMTA filing date and status, not just whether they filed at all — this logic is covered in more depth in our PMTA economics piece
• Check whether the target state maintains its own product registry — a layer that needs separate verification beyond the federal framework
• The rising 2026 enforcement trend is likely to continue; don't treat "it cleared customs before" as a stable long-term assumption — see our logistics deep dive for the practical details on that front

(General information only, not legal advice — consult a lawyer familiar with FDA compliance before making business decisions.)